Stellular Bio
Develops platelet-derived regenerative biologic therapeutics for ocular surface diseases
UndisclosedSeries A
Role not disclosedZC
Ziff Capital Partners
Activity from announced rounds
Activity in this selectionJan 31, 2026 · Jan 1, 2026
Ziff Capital Partners is the firm named in Stellular and ai3Bio coverage, with ai3Bio identifying it as founding investor and co-lead.
Recorded funding activity
Stellular develops biologics for ocular disease. Ai3Bio develops therapies targeting Th17 immune cells. The pending relationship stays in draft while the firm’s event-specific roles are preserved.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- — 0 disclosed · full round size, not this investor’s share